Evidence map›Paper›PMID 38540105›Full record

ArticleBiomedicines2024

Supervised Parametric Learning in the Identification of Composite Biomarker Signatures of Type 1 Diabetes in Integrated Parallel Multi-Omics Datasets.

Jerry Bonnell, Oscar Alcazar, Brandon Watts, Peter Buchwald, Midhat H Abdulreda, Mitsunori Ogihara

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Illuminating diabetesWorld journal of diabetes · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jerry BonnellFrost Institute for Data Science and Computing, University of Miami, Coral Gables, FL 33146, USA.ORCID 0000-0002-7404-9160
Oscar AlcazarDiabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Brandon WattsDiabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.ORCID 0009-0007-6020-141X
Peter BuchwaldDiabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.ORCID 0000-0003-2732-8180
Midhat H AbdulredaDiabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.ORCID 0000-0002-0146-5876
Mitsunori OgiharaFrost Institute for Data Science and Computing, University of Miami, Coral Gables, FL 33146, USA.
University of Miami · US

Funding

Role of macrophages in pancreatic islet graft rejectionK01DK097194 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ABDULREDA, MIDHAT H · 2013 to 2015
$415k
Mechanisms of islet transplant immune toleranceR56AI130330 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ABDULREDA, MIDHAT H · 2017 to 2017
$384k
NIAID NIH HHS R56 AI130330NIDDK NIH HHS K01 DK097194NIDDK NIH HHS K01DK097194
6 · The paper itself

Abstract

backgroundType 1 diabetes (T1D) is a devastating autoimmune disease, and its rising prevalence in the United States and around the world presents a critical problem in public health. While some treatment options exist for patients already diagnosed, individuals considered at risk for developing T1D and who are still in the early stages of their disease pathogenesis without symptoms have no options for any preventive intervention. This is because of the uncertainty in determining their risk level and in predicting with high confidence who will progress, or not, to clinical diagnosis. Biomarkers that assess one's risk with high certainty could address this problem and will inform decisions on early intervention, especially in children where the burden of justifying treatment is high. Single omics approaches (e.g., genomics, proteomics, metabolomics, etc.) have been applied to identify T1D biomarkers based on specific disturbances in association with the disease. However, reliable early biomarkers of T1D have remained elusive to date. To overcome this, we previously showed that parallel multi-omics provides a more comprehensive picture of the disease-associated disturbances and facilitates the identification of candidate T1D biomarkers.

methodsThis paper evaluated the use of machine learning (ML) using data augmentation and supervised ML methods for the purpose of improving the identification of salient patterns in the data and the ultimate extraction of novel biomarker candidates in integrated parallel multi-omics datasets from a limited number of samples. We also examined different stages of data integration (early, intermediate, and late) to assess at which stage supervised parametric models can learn under conditions of high dimensionality and variation in feature counts across different omics. In the late integration scheme, we employed a multi-view ensemble comprising individual parametric models trained over single omics to address the computational challenges posed by the high dimensionality and variation in feature counts across the different yet integrated multi-omics datasets.

resultsthe multi-view ensemble improves the prediction of case vs. control and finds the most success in flagging a larger consistent set of associated features when compared with chance models, which may eventually be used downstream in identifying a novel composite biomarker signature of T1D risk.

conclusionsthe current work demonstrates the utility of supervised ML in exploring integrated parallel multi-omics data in the ongoing quest for early T1D biomarkers, reinforcing the hope for identifying novel composite biomarker signatures of T1D risk via ML and ultimately informing early treatment decisions in the face of the escalating global incidence of this debilitating disease.

Indexed as

biomarker signaturesearly diagnosisintegrated analysislipidomicsmachine learning (ML)metabolomicsmulti-omicsmulti-view architectureparametric modelspreventionproteomicstranscriptomicstype 1 diabetes (T1D)

Identifiers

PMID38540105
PMCPMC10968313
OpenAlexW4392037568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.